Journal of clinical & experimental oncology最新文献

{"title":"Influence of Long-term Abemaciclib, A New CDK 4/6 Inhibitor: Decrease in Liver Metastasis in a Patient Suffering from Metastatic Breast Cancer","authors":"O. Zorn, J. Miller, F. Heirler","doi":"10.4172/2324-9110.1000238","DOIUrl":"https://doi.org/10.4172/2324-9110.1000238","url":null,"abstract":"An 82-year old patient suffering from metastatic breast cancer (FIGO IV D) underwent surgical operations and radiation treatments in the past. From November 29, 2018 until now, the patient was treated with 100 mg Abemaciclib (2 x 50 mg). During therapy, her pain subjectively decreased. No relevant side effects were observed. After 6 months, hepatic metastasis was checked by means of computer tomograph (CT) and a significant reduction of metastasis size was documented.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46053526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Monoclonal Antibodies Treatment","authors":"Lakshmi Vasudha Yrrinki","doi":"10.37532/JCEOG.2020.9(4).248","DOIUrl":"https://doi.org/10.37532/JCEOG.2020.9(4).248","url":null,"abstract":"","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41523110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safe Combination of Cisplatinand Metformin Reverts theMalignant Ascites in a MouseModel to a Solid Tumor byDownregulation of ÎNp63 andInduces Tumor Dormancy via mTOR/ p21 Mechanism","authors":"Sara Gebril, O. El-khawaga","doi":"10.30476/MEJC.2021.86035.1321","DOIUrl":"https://doi.org/10.30476/MEJC.2021.86035.1321","url":null,"abstract":"Currently, combination therapy has become the cornerstone of cancer treatment. The combination of different anti-cancer mechanisms can induce tumor cell quiescence. However, toxicity to normal tissue is the major limitation of existing combined drugs. In this study, Ehrlich ascites carcinoma (EAC) inoculated into mice was targeted with just one dose of cisplatin and later doses of metformin, a safe anti-diabetic drug with an anti-cancer effect, to maintain EAC cells in the quiescent state and secure a longer survival time without tumor recurrence. The group that underwent dual therapy had developed a delayed solid tumor instead of a malignant ascites. Induction of chemo-quiescence in the EAC cells was proven by downregulation of mechanistic target of rapamycin (mTOR) and upregulation of cyclin- dependent kinase inhibitor 1 (p21) expressions. Intriguingly, the conversion of free neoplastic cells into a solid tumor was associated with a significant decrease in ΔNp63 immunostaining in EAC cells. Taken together, a single dose of cisplatin followed by metformin doses could overcome the aggressiveness of malignant ascites by the conversion into a solid tumor, induction of chemo-quiescence and extension of survival time","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43283960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatocellular CarcinomaPost Viral Hepatitis B and C:Application of the PrognosticScore of Singapore","authors":"D. Bacha, O. Belkacem, S. Slama, B. Sâadia, W. Ferjaoui, G. Talbi, L. Gharbi, L. Prasanthi","doi":"10.37532/JCEOG.2020.9(4).245","DOIUrl":"https://doi.org/10.37532/JCEOG.2020.9(4).245","url":null,"abstract":"Surgical resection of hepatocellular carcinoma (HCC) is a major curative option in patients with adequate residual liver function. The risk of recurrence is extremely high. The Singapore liver cancer recurrence (SLICER) is a nomogram that evaluates the 3-year and 5-year recurrence-free survival (RFS) of patients operated for HCC. The objectives of our study were: To apply the SLICER prognostic score to a series of patients operated for a CHC To compare the results found with specific evolutionary data in our patients","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42484101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Iron Overload in the Setting of H63D Gene Mutation and Inrahepatic Cholangiocarcinoma","authors":"F. Numan, Roy Kondepati, Paméla, Wang Yichen, L. Prasanthi","doi":"10.37532/JCEOG.2020.9(3).244","DOIUrl":"https://doi.org/10.37532/JCEOG.2020.9(3).244","url":null,"abstract":"Hereditary hemochromatosis (HH) is characterized by progressive iron deposition and tissue injury secondary to inappropriate intestinal iron absorption. The H63D mutation is a relatively rare cause of symptomatic HH. Heterozygous H63D patients rarely show disease symptoms. The risk of hepatic malignancy as a consequence of HH is largely prevalent in the setting of cirrhosis. Cholangiocarcinoma is the second most common hepatic malignancy. Intrahepatic Cholangiocarcinoma (ICC) secondary to heterozygous H63D HH in the setting of secondary iron overload is a very rare occurrence. This patient was found to have iron overload with H63D heterozygous mutation and cirrhosis. This was a suspicious finding given this usually benign mutation. A CT of the abdomen revealed intrahepatic cholangiocarcinoma. We present a case of this patient with H63D heterozygous`mutation who developed iron overload as the first sign of cholangiocarcinoma. Treatment of the malignancy lead to improvement in the ferritin level.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48383832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adapting to Cancer with Body, Mind, and Heart: Psychological, Psychophysiological Assessment and Management in Sample of Ovarian Cancer Survivors","authors":"C. Pruneti, C. Cosentino, C. Merisio, R. Berretta","doi":"10.4172/2324-9110.1000242","DOIUrl":"https://doi.org/10.4172/2324-9110.1000242","url":null,"abstract":"Objective: Ovarian cancer survivors often develop severe psychological disorders and impairments in social, familial, and sexual functioning. They experience a withdrawal from intimate relationship, fear and body shame, and a condition of unrelenting distress. Heart rate variability (HRV) is a physiological parameter that, when reduced, is index of higher distress. The quantitative observational study aimed at understanding the relationship between psychological adjustment, distress, and quality of life. \u0000 \u0000Methods: 44 women, consecutively recruited at the Oncological service of the Gynecological Dept., filled questionnaires investigating social support, body image, coping strategies and quality of life and recorded short-term HRV. \u0000 \u0000Results: significant correlations appeared between: quality of life functioning scales and body image, perceived social support and coping strategies; perceived support from the significant other and HRV (r=339 p <05), role functioning and HRV (r=479 p<001). Simple regressions on HRV showed the effect of the significant other’s support (F=4.27 p<05) and of role functioning (F=9.810 p<001), while body image showed its effect on quality of life (F=4.18 p<05). Multiple regression on HRV showed the effect of body image (β=453), support from friends (β=-435) and avoidance (β=-391) while fatalism showed an effect on quality of life (β=364, p<05). \u0000 \u0000Conclusion: Higher concerns on body image seem linked to a worsened day-to-day life. Reporting these concerns contributes to raise HRV, while better emotive disclosure reduces emotional distress. Social support positively influences quality of life and HRV. Fatalism facilitates cancer acceptance process. Proper emotive disclosure may have a positive impact on life quality.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48875830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does Infiltrative Anesthesia Improve Post-operative Morbidity after Axillary Lymph Node Dissection in Patients of Breast Cancer? â A Prospective Study from a Tertiary Care Center in North India","authors":"S. An","doi":"10.4172/2324-9110.1000240","DOIUrl":"https://doi.org/10.4172/2324-9110.1000240","url":null,"abstract":"Background: The role axillary lymph node dissection (ALND) in staging, prognostic assessment and local control in patients of breast cancer with clinically evident disease in the axilla is well established. ALND has its share of morbidity in the form of restriction of range of motion of arm, pain, paraesthesia and lymphedema influencing quality of life. This prospective study evaluates the effect of infiltrative anaesthesia injected along the nerve bundles exposed during ALND in reducing the restriction of range of motion of arm and pain scores following ALND. \u0000 \u0000Methods: A total of 60 ALND in patients of operable invasive breast cancer were randomized in to two groups:- Group 1: The control group where patients of ALND were managed in the postoperative period with standard analgesia of injection acetaminophen 1 gm 8 hourly and early arm and shoulder movements from the evening of the procedure. Group 2: The test group had 5 ml of 0.125% Bupivaccaine injected each around the three nerve bundles exposed during ALND along with early arm and shoulder exercises and standard analgesia similar to the control group. Medical records of patients were analysed for age, laterality, clinical staging, histopathological parameters and surgical complications. Range of motion of ipsilateral at the shoulder and pain scores as recorded by visual analog scale (VAS) were objectively noted on day 0 to day 28 postoperatively at various intervals. \u0000 \u0000Results: The range of motion at ipsilateral shoulder was measured by flexion, abduction and extension. The degrees of flexion and abduction were found to have statistically significant difference on Days 0, 3 and 7 in the test group in comparison to control group (p=0.001 for flexion on all Day 0,3 and 7 and p=0.009 for Day 0, p=0.001 for Day 3 and p<0.001 for Day 7 for abduction). Extension was better in the test group on Days 0 and 3 (p<0.001 and p=0.005 respectively). Pain scores assessed by VAS were significantly lower in test group when compared to control group on Days 0,1, 3 and 7 (p ≤ 0.01). There was no statistically significant difference in the restriction of flexion, extension and abduction and pain scores on Day 28 between the groups. Analgesia requirement was significantly reduced in the test group on days 0 and 1 (p ≤ 0.05). \u0000 \u0000Conclusion: Infiltrative anaesthesia with 0.125% bupivaccaine along the nerve bundles exposed during ALND improves range of motion at shoulder and pain scores in the immediate postoperative period in patients of breast cancer.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42777538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of Abemaciclib, a New CDK 4/6 Inhibitor, Decrease in Potassium Electrollytes and Urea in a Patient Suffering from Metastatic Breast Cancer","authors":"O. Zorn, F. Heirler","doi":"10.4172/2324-9110.1000235","DOIUrl":"https://doi.org/10.4172/2324-9110.1000235","url":null,"abstract":"A 46-year old patient suffering from metastatic breast cancer (FIGO IV D) underwent various chemotherapies and radiation treatments in the past. From November 4, 2018 the patient was treated with 300 mg Abemaciclib (2 × 150 mg). During therapy, her pain subjectively decreased. After 14 days the patient suffered nausea, emesis and exsiccation. She was therefore hospitalized and intensively monitored. Leukopenia and anemia on a common scale were treated in the usual way. Despite normal retentions, we detected a significant decrease in potassium and calcium. Surprisingly, we also detected a decrease in urea. Because of the continuous decrease in potassium and calcium, we substituted the electrolytes. After two weeks, all labor","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42160302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preparation of NSC 631570 (UKRAIN) in the treatment of malignant melanoma","authors":"pWassil Nowickyp","doi":"10.4172/1948-5956-C12-155","DOIUrl":"https://doi.org/10.4172/1948-5956-C12-155","url":null,"abstract":"","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70962103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patterns of Outcome in Human Papilloma Virus Positive Oropharyngeal Squamous Cell Carcinoma Treated Primarily with Radical Radiotherapy","authors":"Hao-Yue Lu, Anni Chen, I. Iankov, M. Min, R. Gowda, R. Mukherjee, D. Roos, H. Le","doi":"10.4172/2324-9110.1000232","DOIUrl":"https://doi.org/10.4172/2324-9110.1000232","url":null,"abstract":"Introduction: The aims of this study were to determine patterns of outcome and prognostic factors in human papilloma virus positive oropharyngeal squamous cell carcinoma (OPSCC+) treated primarily with radical radiotherapy. \u0000Materials and methods: We identified 54 patients at a tertiary hospital in South Australia who received treatment with curative intent for OPSCC+ with radical radiotherapy ± chemotherapy or cetuximab from 1st January, 2010 to 31st  March, 2017. We explored the effect of patient, tumour and radiotherapy factors on treatment outcomes. The primary endpoint was overall survival and the secondary endpoint was disease-free survival. \u0000Results: The median age was 59, with most patients being male (82%). The majority had advanced disease (89% stage IV). The median follow-up was 22.5 months. The one-year and two-year overall survival and disease-free survival rates were 89% and 79% and 77% and 68% respectively. Active smoking during radiotherapy was associated with trends to shortened overall survival (p=0.084) and reduced time to recurrence (p˃0.1). However, there was no statistically significant relationship between any other patient, tumour or treatment factors and disease-free or overall survival. \u0000Discussion: Despite advanced stage at presentation, radiotherapy ± concurrent systemic therapy results in favorable outcomes for OPSCC+. Active smoking during radiotherapy may compromise overall survival. We strongly recommend smoking cessation prior to commencing radiotherapy for OPSCC+. In addition, we note that smokers involved in de-intensification trials may be at increased risk of poor outcomes.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48650332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}